Fig. 2From: SRC kinase-mediated signaling pathways and targeted therapies in breast cancerSRC kinase configuration with Tyr530 phosphorylation or Tyr419 phosphorylation, respectively. SRC activity is inhibited when the phosphorylated Y530 at the CÂ-terminal region binds to the SH2 domain, which will prevent the interaction of substrate proteins with the kinase domain (left panel). Dephosphorylated Y530 will induce the disassociation of the C-Âterminal region from the SH2 domain, which allows substrate protein access to the catalytic kinase site in the SH1 domain, and be subsequently phosphorylated by SRC kinase (right panel)Back to article page